Somaxon Pharmaceuticals Inc. continued to slog through the crowded insomnia market with Silenor (doxepin) during the second quarter, growing net sales to $6.2 million – a 170 percent increase over the $2.3 million sold last quarter, and ahead of the $4 million analysts had expected.